The report highlights Astellas' progress in its Corporate Strategic Plan 2021 (CSP2021), which focuses on transforming the company into a cutting-edge, VALUE-driven life science innovator. The report covers key achievements, including the progress of strategic goals, organizational health goals, and sustainability initiatives. The company updated its materiality matrix, launched a new program for health system strengthening, and provided disclosure on the Task Force on Climate-related Financial Disclosures (TCFD) recommendations. Astellas also made significant progress in advancing its Focus Area approach, expanding its pipeline of innovative therapies in areas such as cell therapy, gene therapy, and immuno-oncology. Key highlights include the launch of PADCEV in the EU, the submission of fezolinetant NDA to the US FDA, and the achievement of additional approvals for XTANDI.
Go back to company
Astellas Pharma Inc 2022 Integrated Report
Issuing Company Astellas Pharma Inc.
Report Type Integrated Report
Report Language EN
Report Filesize 31.43 MB
No. of Pages 92 pages
Reporting periodApril 1, 2021-March 31, 2022
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDG; others
Materiality Assessmenttrue